SEC Comment Letter for GT Biopharma, Inc. (GTBP) (CIK 0000109657) (GTBP) — Sep 20, 2019
GT Biopharma, Inc. (GTBP) (CIK 0000109657)
Date: Sept. 20, 2019 · CIK: 0000109657 · Accession: 0000000000-19-013809
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233748
Letter
September 20, 2019 Anthony J. Cataldo Chief Executive Officer GT Biopharma, Inc. 9350 Wilshire Blvd. Suite 203 Beverly Hills, CA 90212 Re:GT Biopharma, Inc. Registration Statement on Form S-1 Filed September 13, 2019 File No. 333-233748 Dear Mr. Cataldo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Gary R. Henrie, Esq.
Show Raw Text
September 20, 2019
Anthony J. Cataldo
Chief Executive Officer
GT Biopharma, Inc.
9350 Wilshire Blvd. Suite 203
Beverly Hills, CA 90212
Re:GT Biopharma, Inc.
Registration Statement on Form S-1
Filed September 13, 2019
File No. 333-233748
Dear Mr. Cataldo:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Gary R. Henrie, Esq.